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variant angina and normal coronary angiograms. Our results suggest 
that basal production/relcaseof NO may not be decreased at spastic 
sites in these patients. WC did not investigate the NO-generating 
capacity or vasomotor responses to vasoconstrictor stimuli at the site of 
spasm. Thcrcfore. we cannot conclude that the NO-generating capac- 
ity is augmented at spastic sites. 
Tousoulis ct al. proposed an intriguing hypothesis that atheroscle- 
rotic human corona? arteries can rcgcnerate basal NO production 
from an abnormal source. such as the inducible isoform of NO 
synthase. This hypothesis is based on the fact that patients with variant 
angina have varying degrees of coronary atherosclerosis and that the 
inducibie NO synthase is found in some human coronary arteries 
segments with atherosclerotic lesions. It has heen demonstrated that 
total NO-generating capacity is altered during the process of athero- 
sclerosis (I); however, its precise mechanism has not been well 
understood. There is substantial evidence demonstrating that 
endothelium-dcrivcd NO-rclatcd vasodilation is impaired car!y in 
atherosclerosis (1). However, the results of recent investigations (2-1) 
suggest that endothelial constitutive NO synthase messenger RNA and 
NO protein production are augmented in atherosclerotic vessels. 
These findings suggest that altered NO-related vasomotion during 
athcrosclcrotic process might result from an increased breakdown of 
NO but is not necessarily related to expression of inducible NO 
synthase. It is unknown whether NO that is generated from inducible 
NO synthase contributes to regulation of vasomotor tone. Therefore. I 
believe that the currently available data are not sufficient to support 
tile hypothesis hy Tousoulis et al. Much more investigation remains to 
be done before their hypothesis is substantiated. 
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Cost Efficacy Modeling of Catheter Reuse 
for Percutaneous Transluminal 
Coronary Angioplasty 
I wish to comment on the report by Mak et al. (1) and indirectly on the 
accompanying editorial by Natarajan and Williams (2) Although the 
report by Mak et al. is well wriiten and discusses an impttant topic, it 
seems to me that the authors have made several major assumptions in 
their cost analysis that have gone unstated and unexamined. In 
particular, the authors assume that the price, or cost, of balloon 
catheters is a fixed Quantity and would not change if the results of their 
study were applied widely, even for a subset of patients with stable 
angina. Would the medical device industry really be able to continue to 
charge the same price for balloon catheters if the total number sold 
was reduced by 80% (“best” ease)? How can this posstbly make 
economic sense, since presumably the marginal cost for the production 
and sales of any product is dependent. to some extent. on the volume 
of sales. The authors might ~argue that their analysis is one of 
microeconomics and that the “system” would not be affected if the 
results of their analysis were applied only on a small sca]c..‘to their 
medical center. say. Yet their motivation is clearly macroeconomic’in 
scope hccause they claim that “If coronary angioplasty equipment 
could he reused [based on the results of this and other studies]. the 
total cost could bc potentially reduced hy more than Sl billion per year 
in the Ifnited States.” The systemic implications of this type of inquiry 
arc also implied hy the accompanying editorial. which refers to the 
yearly total charges for angioplasty in the United States of $6 billion. 
The reason that this glaring oversight is important is that this 
report, and others like it. will be used by policymakers interested only 
in short-term cost reduction and not on the larger question of who 
should bear the cost of innovation, including innovation that might 
ultimately (but not necessarily immcdiatcly) reduce overall costs and 
improve care. When policymakers advocate reuse. even in “low risk” 
settings (or any such “cost reduction”). they are reducing the incentive 
for entrepreneurs and inventors to develop new technologies that 
might ultimately improve outcomes. This is not to c~cuse manufactur- 
ers from pricing devices or drugs so as to result in unreasonably high 
protits, but it needs to be remembered that the costs of developing any 
new medical technology arc large and growing. and industry hears the 
majority of such costs. Thnw costs arc in turn huilt into the price of 
each device sold, and if fewer are sold, either the price must rise 
concomitantly or innovation will simply no1 occur. 
Another cost not mentioned is that associated with the medicolegal 
ramifications of reuse. Although reuse of balloon catheters labeled 
.‘single-use only” is not a prima facie violation of standard of care, it 
certainly transfers some of the medicolegal burden to those who 
willingly violate Food and Drug Administration labeling. Thus, one 
can reasonably assume that in some percentage of cases where reused 
catheters cause a complication or additional procedure that might not 
have occurred with d new catheter. a patient will become a plaintiff 
with a willing attomzi and medical expert willing to sa:: tbat reuse 
violates standard of care. Furthermore, in some of those cases the jury 
will agree with the pi&LZ and award damage costs on the order of 10 
to 20 times actual costs. If this series of assumptions is entered into the 
cost-ethcaq model developed by the authors, it might well shift the 
cost-efficacy toward single use. 
A final issue that was not discussed in the report by Mak et al. 
relates to the way in which some part of hospital cost savings are 
implicitly shifted as expenses for physicians. without any clear mech- 
anism for the physicians to recoup those extra expenses. In particular. 
procedures performed with reused catheters are likely to take longer 
(Xl vs. 68 min was used in the study by Mak et al.), with much of that 
extra time requiring exposure of the operator to potentially harmful 
fluoroscopic radiation. Thus, the hospital saves money on catheters 
while physician reimbursement per unit time fails (because he or she is 
not likely to collect more for the same procedure, which takes longer 
simply because of reuse), and his or her long-term risk of radiation 
exposure rises. Perhaps when physicians and hospitals are in a true 
revenue-sharing relationship (such as in a provider-& health 
maintenance organization or foundation such as the Cleveland Clinic). 
this cost shifting is irrelevant, but in most delivery systems and 
hospitals. both for-profit and not-for-profit, including our own Univer- 
sity Medical Center, cost savings by the hospital are not transferred to 
the physicians even if they incur additional expenses. This is, of course, 
an issue that goes well beyond that of balkron catheters and gets into 
the matter of how willing we should be, as physicians and reseatehers. 
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to assist hospitals in their cost-saving measures when such measures 
are potentially detrimental to our patients and ourselves. 
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We thank Lesh for his comments. Despite the limitations of our study, 
we believe that our models were instructive in illustrating cost savings 
associated with reuse of balloon catheters in various scenarios. We 
agree that the cost of balloon catheters may vary as a function of a new 
“reuse” era in interventional cardiology. As such, we have constructed 
a sensitivity analysis based on the different costs of balloon catheters in 
our report (I) (Fig. 2). As the cost of balloon catheters increases, the 
potential for savings is also greater. This analysis preempts Lesh’s 
criticism. 
Medicolegal problems may arise after complications from any 
medical or surgical treatment. Indeed, with regard to reuse of balloon 
catheters several other clinical and technical issues require further 
consideration (2). An important point highlighted by the study by 
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Plante et a!. (3) was the possibility of a higher complication rate when 
reusing catheters. However..a preliminary report from another Cana: 
dial study (I) suggested that reuse of balloon catheters “,..c not 
asxxiatrd with an increase in complications. Furthermore, a reanalysis 
of the study’by Plantc et al. (3). using multivariate~logistic regression 
modeling. also suggested that reuse of h.:lloon catheters was not 
associated with increased in-hospit complication rates (5). If these 
results arc replicated in other large, randomized trials. then it would 
indicate that reusing balloon catheters may be as safe as using new 
ones, provided that the process of cleaning, sterilization, reprocessing 
and packaging is performed properly. In summary, for reuse to be 
practiced widely in the United States, there has to be some form of 
discussion among representatives from policymakers, industry and 
health cart providers. 
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